can selectively silence disease-causing genes. [1] [2] [3] Although promising for cancer treatment, the low bioavailability of siRNA has hampered their translation into clinical use. Typically, due to their net negative charge and relatively large size, synthetic siRNA does not readily cross biological barriers. In addition, siRNA duplexes are quickly degraded by serum and intracellular ribonucleases. As a consequence, efficient systemic delivery necessitates the use of suitable carriers to physically protect siRNA therapeutics and facilitate their cellular uptake, while still maintaining their functionality. Because of their passive tumor targeting ability, 4 nanoparticles are desirable delivery vehicles for cancer therapy. However, both micrometer and nanometersized carriers are suitable for siRNA delivery depending on the specific target tissue. For instance, immunotherapy of kidney or pancreas cancers, melanomas, or other solid tumors requires the effective delivery of siRNA by micron-or sub-micron sized vectors to blood mononuclear cells or dendritic cells. 5 For example, treatment of lung-associated diseases by siRNA rely on the use of particles with aerodynamic diameters of 1-10 μm. 6 Hence, a number of of intracellular redox-responsive nanoporous poly(ethylene glycol)-poly-L-lysine particles, NPEG-PLLs, for the efficient and safe release of a low dose of siRNA (31 nM) designed to target the anti-apoptotic factor survivin in prostate cancer cells. Survivin is a protein highly expressed in the majority of malignant tumors compared to normal tissues. 22 It is a member of the Inhibitor of Apoptosis Protein (IAP) family, thus acting as a suppressor of apoptosis and favoring tumor progressions. 23, 24 In addition, it has been widely demonstrated that the overexpression of survivin causes resistance to radiation and chemotherapeutic agents, and it has been reported to correlate with poor prognosis in cancer patients. 22 Several strategies, such as small molecules, peptidomimetic and antisense oligomers (including siRNA) have been reported to suppress survivin expression in cancer. 22 However, the available therapeutic approaches have yielded only partial positive responses in clinical trials because of the inefficient in vivo delivery and poor bioavailability of naked siRNA. In this context, our NPEG-PLLs offer a positively charged nanoporous template to entangle negatively charged anti-survivin siRNA, while the PEG chains provide a redox-responsive crosslinker to stabilize the nanoporous carriers against dilution and competitive serum protein binding. Our study demonstrates that NPEG-PLLs may effectively protect siRNA from the adverse conditions of the extracellular and intracellular environment. The exposure of prostate cancer cells to survivin-directed siRNA, delivered through NPEG-PLLs along with a low dose of paclitaxel, resulted in improvement of the cytotoxic activity of the anticancer drug. This feature highlights the potential of this carrier to become a support for therapeutic intervention for cancer treatment.
EXPERIMENTAL SECTION
Australia). After blotting dry, the grids were air dried overnight and then analyzed using TEM (Philips CM120 BioTWIN) operated at 120 kV. To determine the pore size, NPEG-PLLs were incubated in 0.5 mg mL -1 M W 500 kDa and M W 2000 kDa FITC-dextran for 30 min in PBS at room temperature, washed twice with PBS and analyzed by confocal laser scanning microscopy (CLSM), using a Leica TCS SP2 confocal system equipped with an HCX PL APO lbd.BL 63×
1.4 NA oil objective. The images were then analyzed using ImageJ software. Potentiometric titration analysis was applied to determine the amine and carboxyl groups content of the NPEGPLLs and to estimate the degree of particle crosslinking. NPEG-PLLs (0.3-1 mg) was dispersed in 0.5 mL of 0.15 M NaCl, and the pH of the suspension was initially adjusted to 11 using 0.1 N NaOH. Next, the suspension was titrated with 8 mM HCl to pH 3. PLL dissolved in 0.15 M NaCl, and 0.15 M NaCl solutions were titrated in the same way as controls. To determine the carboxyl/amine groups ratio, NPEG-PLLs were dispersed in 0.5 mL of 0.15 M NaCl and the suspension initially adjusted to pH 3 using 0.1 N HCl. The suspension was titrated to pH 11 using 4 mM NaOH. The pH of the solutions was measured after each addition by a pH meter (microprobe Mettler-Toledo, Inc. Columbus OH).
Determination of NPEG-PLL Crosslinking Degree. The crosslinking degree of NPEG-PLL was determined by equilibrium swelling experiments applying the Flory Rehner theory (eqn (1))
that was recently applied to the determination of microgels structure 25 :
where ʋ is the crosslinks density (molcm -3 ), χ is the Flory polymer-solvent thermodynamic interaction parameter, 1 is the molar volume of water, 2 is the equilibrium swollen polymer volume fraction measured in 0.2 M NaCl, and 2 is the relaxed polymer volume fraction. 2 and 2 were evaluated taking into account the polymer mass per particles and NPEG-PLL diameter in the swollen and dry state. The extent of swelling depends on crosslinking the degree, the concentration of ionic groups within the network, the degree of ionization of PLL, and the electrolyte concentration in solution. As the swelling of NPEG-PLLs was carried out in 0.2 M NaCl, the ionic osmotic pressure difference between the particle interior and exterior became reduced and the swelling controlled only by the neutral component of the network. 26 A weighted average was used to calculate a value of χ=0.44 (based on mole fractions of PLL and PEG)
repeat units in the NPEG-PLL.
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Post Loading of siRNA into NPEG-PLLs. An aliquot of 10 μL of NPEG-PLLs (1.3 × 10   7 particles μL -1 ) was incubated in DNase/RNase free 0.5 X PBS buffer with 10 μL of siRNA (7.7 µM) for 30 min, centrifuged and washed several times in PBS. The siRNA or AF488-siRNA uptake into the NPEG-PLLs was measured using a NanoDrop spectrophotometer by recording the absorbance at 260 nm or 495 nm of the solutions before and after adsorption taking into account the absorbance of three washing steps. The number of NPEG-PLLs per microliter (1.3 × 10 7 NPEG-PLL μL -1 ) in the sample was quantified using flow cytometry.
Thermal Stability of siRNA-Loaded NPEG-PLLs. The thermal denaturation of the released siRNA was analyzed after NPEG-PLL degradation by protease. An aliquot (10 µL) of protease from Streptomyces griseus dissolved in PBS buffer (1 mg mL -1 ) was incubated at 37 °C overnight with 50 µL of NPEG-PLLs (1.3 × 10 7 particles µL -1 ). To follow the siRNA thermal denaturation, PicoGreen, a double-stranded selective dye, was used to fluorescently stain the duplex and the fluorescence intensity of the intercalated dye was measured using a Horiba YvonJacob FL3-22 fluorimeter as a function of temperature. PicoGreen has an excitation maximum at 480 nm and an emission maximum at 520 nm. An aliquot of 1 µL siRNA (21 µM) was diluted to 250 µL PBS buffer and 0.5 µL PicoGreen (3.2 µM). The fluorescence emission of the mixture was recorded in the range 20-80 °C. The thermal denaturation of the released siRNA was analyzed after NPEG-PLL degradation by protease.
In Vitro Serum and Plasma Stability of siRNA-Loaded NPEG-PLLs. The serum stability of AF488-siRNA loaded into NPEG-PLLs was characterized using a NanoDrop spectrophotometer.
AF488-siRNA-loaded NPEG-PLLs were incubated for 4 h in PBS pH 7.4 containing 10% FBS and for 3 h in human plasma K 2 EDTA. After centrifugation, the siRNA displaced from NPEG-PLL by serum proteins was evaluated by measuring the absorbance at 495 nm of the supernatant and subtracting the background absorbance. To evaluate the colloidal stability of NPEG-PLLs in plasma, 7 × 10 7 AF488-siRNA-loaded NPEG-PLLs were incubated with human plasma K 2 EDTA for 48 h. Samples were monitored by confocal microscopy to assess whether the plasma protein adsorbed onto NPEG-PLL promoted particle aggregation. The adsorption of plasma protein on the NPEG-PLL surface was verified by ζ-potential measurements.
In Vitro Glutathione, GSH, and Protease-Induced Degradation of NPEG-PLLs. Flow Cytometry. PC-3 cells were seeded in 6-well plates for 24 h. Cells were then treated with AF488-labeled NPEG-PLLs at a particle/cell ratio of 72:1 or 125:1 for different time intervals at 37 °C and 5% CO 2 . After the treatment (specifically, 0, 6, 16 and 24 h), cells were washed with PBS three times and harvested by trypsinization followed by centrifugation at 400 g for 5 min. Colocalization analysis was performed with Imaris software (Bitplane AG, Zürich, Switzerland).
Super-Resolution Structured Illumination Microscopy (SIM).
PC-3 cells were cultured as described for the deconvolution experiments. Cells were then incubated with AF488-NPEGPLLs (125 particles/cell) for 1 h (37 °C, 5% CO 2 ) followed by three washes with standard growth medium to remove non-internalized particles. After 120 h incubation (37 °C, 5% CO 2 ), the cells were fixed, permeabilized and immunostained as described for the deconvolution microscopy experiments. Mouse anti-human LAMP1 monoclonal antibody and AF568-labeled goat anti-mouse IgG were applied at the same concentrations to visualize the lysosomes, while the nuclei were stained with Hoechst 33342.
LAMP1 is the lysosomal-associated membrane protein 1 which localizes on the lysosomal membrane. We used a fluorescently-labeled antibody recognizing this protein in order to visualize lysosomes and the colocalization between nanovectors and lysosomes.
Vectashield was used as mounting medium (Vector Laboratories, USA). SIM experiments were carried out with an Applied Precision DeltaVision OMX V4 Blaze Structured Illumination
Microscope using an Olympus 60×, 1.24 NA oil objective, 405 nm, 488 nm, and 568 nm laser illumination, and standard excitation and emission filter sets. Raw images were acquired at a 125-nm z-step size, aligned and reconstructed in three dimensions with softWoRx 6.1.3 (Applied Precision) software.
Fluorescence Lifetime Imaging Microscopy (FLIM).
PC-3 cells were cultured as described for the deconvolution experiments. FITC-labeled NPEG-PLLs were added to cells at a particle/cell ration of 500:1 and incubated for 1 h (37 °C, 5% CO 2 ) followed by three washes with standard growth medium to remove non-internalized particles. Cells were then incubated (37 °C, 5%
CO 2 ) and imaged at specific time points (0. was added for the last 48 h. Cells were collected and counted in a particle counter (Coulter Counter, Coulter Electronics, Luton, UK). Each experimental sample was run in triplicate.
RESULTS AND DISCUSSION
NPEG-PLL Synthesis and Chemical Characterization. The redox-sensitive NPEG-PLLs were prepared by infiltrating PLL into MS particles followed by PLL crosslinking using PEG-Nhydroxy-succinimide-disulfide linkers (PEG-NHS-disulfide) (Supporting Information, Figure   S1 ), and subsequent removal of the MS templates (Scheme 1). MS particles with a bimodal pore structure (smaller mesopores in the 2-3 nm range and larger mesopores between 10-40 nm) 19, 20 were used as templates. A PEG-NHS disulfide crosslinker was selected to introduce redox sensitive crosslinking into the NPEG-PLLs. The rationale for using a redox-responsive polymeric drug delivery system is the significant difference in redox potentials between extracellular and intracellular environments. It has been reported that in the cytosol and nuclei the concentration of glutathione (GSH), the most abundant redox agent in mammalian cells, can reach 10 mM, whereas outside the cell, the concentration drops to approximately 2-20 µM. 29 Hence, NPEG-PLLs are designed to preserve the particle integrity in the oxidizing bloodstream, whereas in a intracellular environment the particles are subjected to high GSH concentrations, which is expected to promote cargo release. In addition, it is noted that the proteolytic activity in the extracellular environment is negligible; hence, NPEG-PLLs can be potentially degraded only by lysosomal proteases. The amount of infiltrated PLL (0.2 mg g -1 of MS) was determined by monitoring the difference in the AF488-PLL fluorescence in solution before and after adsorption.
The PLL mass of a single NPEG-PLL (0.6 pg/particle) after dissolution of the template was determined by quantifying the amount of AF488-PLL in an aliquot of NPEG-PLLs using a UVvis calibration curve and flow cytometry to count the number of particles suspended in the aliquot. The residual content of amine groups after crosslinking was evaluated by potentiometric titration of NPEG-PLL suspension (Supporting Information, Figure S2a ).
Scheme 1. Schematic Illustration of siRNA Encapsulation into NPEG-PLL via Mesoporous Silica Templating
The measured fraction of amine groups was used to determine that the crosslinking degree was 40% (PEG unit/lysine unit), corresponding to 0.0018 mol cm -3 density of effective crosslinked chains. These results indicate that a single NPEG-PLL is composed of 27% (w/w) PLL and 73%
(w/w) PEG, and the single particle mass, taking into account both polymeric components, swollen NPEG-PLLs acquired using structured illumination super-resolution microscopy (SIM), whose lateral resolution is 100 nm, (Figure 1d ) show a highly porous structure. As most of the serum/plasma proteins have a hydrodynamic diameter lower than 25 nm, 31 these results suggest that the NPEG-PLL may be permeable to the proteins during in vitro transfection experiments. ζ-potential measurements reveal that the NPEG-PLL surface was positively charged (+20 ± 3 mV) in 10 mM NaCl and slightly negatively charged (-6 ± 2 mV) in PBS. Interestingly, NPEG-PLLs suspended at high concentration in Milli-Q organize in string-like structures 32 (inset Figure 1b) .
It was recently reported that colloidal particles with a dielectric constant mismatch with the surrounding solvent acquire a dipole moment in a homogeneous external electric (magnetic)
field. 32 The resulting dipolar interactions can lead to assembly of the particles into string-like clusters. The uneven crosslinking of NPEG-PLL probably generates a weak permanent dipole that induces a similar assembly of particles in water.
Complexation of siRNA with NPEG-PLLs. The siRNA directed against survivin (siSurv; MW:
13 330 g mol -1 ) was post-loaded into the crosslinked NPEG-PLL network in phosphate buffer (0.5 x PBS, pH 7.5) using electrostatic interactions. Compared to other methods this procedure would allow the facile mixing of the NPEG-PLL suspension and siRNA prior to patient treatment without any purification steps and with a fine control on particle size distribution.
The nanoporous positively charged polymeric particles provide a scaffold to encapsulate oligonucleotides and other negatively charged biomacromolecules by fast diffusion through the permeable nanoporous structure and in situ complexation with the polycation component. In addition, the co-delivery of siRNA and small molecular weight hydrophobic drugs is feasible by covalent conjugation of drugs to the polymeric backbone of NPEG-PLL.
The siRNA loading into the particles was evaluated by measuring the absorbance at 260 nm of the solutions before and after adsorption, and confirmed by fluorescence microscopy. The N/P ratio (i.e., the ratio of moles of PLL amine groups to RNA phosphate groups) is 18. Due to the nanoporosity and PLL amine groups, NPEG-PLLs show a good adsorption capacity for siSurv 
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To verify the ability of the NPEG-PLLs to disassemble and release intact siRNA, treatment with the reducing agent (GSH) and proteolytic enzymes (1 mg mL -1 protease from Streptomyces griseus) was performed. Degradation experiments were performed in 10 mM reduced GSH in PBS solution at 37 °C, mimicking the cytosolic milieu. NPEG-PLLs were fluorescently labeled using AF488 and the fluorescence of the soluble supernatant, after centrifugation of the nondegraded particles, was monitored over 24 h. The complete degradation of NPEG-PLL by GSH occurred within 24 h. Fluorescence emission of the supernatant isolated from a NPEG-PLL suspension, after centrifugation, and exposed to a large excess of GSH (10 mM) in PBS at 37 °C, was analyzed (Supporting Information, Figure S3a ). The curve exhibits a plateau indicating the degradation process was completed. This is also corroborated by the absence of residual NPEG-PLL in the vials after centrifugation.
Furthermore, treatment with protease at 37 °C for 8 h caused degradation of the NPEG-PLLs, resulting in a green solution (Supporting Information, Figure S3b ). These results confirm that the NPEG-PLLs contain unmodified lysine groups which are known to be the sites of cleavage by proteases such as trypsin. 33 The integrity of siRNA released from NPEG-PLL was studied after protease degradation by measuring the melting temperature of the siRNA duplex (Supporting Information, Figure S4 ). Specifically, both the released and native siSurv showed comparable melting temperatures (40 °C), indicating that the binding and the disassembly process do not compromise the integrity and stability of the siRNA double strand.
NPEG-PLL Stability in Serum and Plasma. Cationic transfection vectors often display poor
efficiency in vivo due to their aggregation with negatively charged proteins in serum. 34 Hence, serum/plasma stability of NPEG-PLL loaded with siRNA must be tested to evaluate the application of NPEG-PLLs as a systemic delivery system of siRNA. The NPEG-PLLs retained their integrity and demonstrated excellent colloidal stability in the presence of plasma proteins at 37 °C for up to 48 h without any change in size or evidence of aggregation (inset Figure 1c) . The adsorption of plasma protein on NPEG-PLL surface was verified by ζ-potential measurements.
After incubation with human plasma, the NPEG-PLL surface charge became slightly negative (-8 ± 2 mV), indicating an effective surface coverage by a protein corona.
In addition, since plasma proteins are able to diffuse into the NPEG-PLLs and potentially displace siRNA molecules bound to the NPEG-PLL scaffold, we performed experiments aimed at evaluating the capability of plasma proteins to compete with siRNA for electrostatic binding.
To this purpose, NPEG-PLLs loaded with AF488-siRNA were incubated in PBS at pH 7.4
containing 10% FBS and 100% human plasma for 3 h and 4 h, respectively. After incubation, the amount of siRNA displaced from NPEG-PLLs by serum proteins was evaluated by quantifying the fluorescent intensity of the supernatant. We found that NPEG-PLLs stably bind siRNA molecules, as only 5% of loaded siRNA was displaced by negatively charged serum proteins.
The high PEG content of NPEG-PLLs most likely contributes to the high serum stability by providing a steric shield.
In Vitro NPEG-PLL Cell Cytotoxicity and Intracellular Trafficking. We evaluated the effect of NPEG-PLLs on the viability of PC-3 prostate cancer cells using an MTS assay. Because of its positive charges, a low concentration of PLL (25 µg mL -1 ) is highly toxic for cells. 33, 34 However, survival of PC-3 cells was unaffected upon a 96-h incubation with up to 1000 NPEG-PLL/cell, a particle amount corresponding to a concentration of 44 µg mL -1 of NPEG-PLL (Figure 2a ). We hypothesize that PLL which has been partly neutralized and immobilized by PEG crosslinking is advantageous compared with free PLL because the nanoporous structure can shield the polycation-mediated toxicity. In addition, AF488-labeled NPEG-PLL appeared to be tightly surrounded by lysosomes after internalization, as indicated by the staining for the specific marker LAMP1 (Figure 3a ). This would suggest that NPEG-PLLs are effectively internalized by the cells and progressed to acidic environment as they were docked by lysosomes. This observation is consistent with intracellular processing reported for other micrometer-sized particles. 37, 38 It is also noted that a fraction of internalized NPEG-PLLs (arrows in Figure 3) were not surrounded by the lysosomal compartment after incubation for 24 h. confirmed the quenching effect observed by FLIM (Supporting Information, Figure S6 ). The decrease in size as a function of incubation time (Supporting information, Figure S7) indicates that NPEG-PLLs slowly degraded by either lysosomal proteases or reducing agents, eventually completely degrading after 120 h incubation. However, as the redox degradation by GSH occurs in the cytosol, our data suggest that the vesicular compartments wrapping NPEGPLLs may be leaky and permeable to cytosolic components. It has already been reported that PLL modified with PEG exhibits a cell membrane penetrating effect. 43, 44 In addition, cationic amphiphilic peptides with lysine amino acids, are known to induce a pH-independent membrane destabilization by cationic interactions with the endosomal/lysosomal membrane. 45 SIM imaging with a 3D illumination pattern, 3D-SIM, provided insight into the final fate of NPEG-PLLs at long incubation times (120 h). In comparison with deconvolution and FLIM microscopy, SIM images allow higher particle localization accuracy. Figure 6 shows green fluorescent fragments with a size of approximately 100-200 nm, suggesting NPEG-PLLs degraded over time. In addition, we found no evidence of colocalization between NPEG-PLL or particle debris and lysosomes/late endosomes after 120 h incubation ( Figure 6 ). This confirms either intact NPEG-PLL or particle debris escape the lysosomes/late endosomes and access the cytosol to disassemble and eventually release siRNA. Survivin Silencing by siSurv-Loaded NPEG-PLLs in PC-3 Cells. We next evaluated the ability of NPEG-PLL to deliver a siRNA directed against survivin within PC-3 cells.
Specifically, cells were exposed for 72 h to pristine NPEG-PLLs, siScr-and siSurv-loaded NPEG-PLLs (particle/cell ratio of 1000:1; 0.0022 µg/cell). The NPEG-PLL-mediated delivery of the intact siSurv was indirectly evaluated based on the expression levels of the target protein by western immunoblotting. The capability of NPEG-PLLs to deliver siSurv was compared to that of a commercially available cationic lipid-mediated transfer, namely Lipofectamine2000 (LP) ( Figure 7 ). It is noted that safe and efficacious delivery of nucleic acids in vivo using Lipofectamine2000 is not feasible due to the toxicity, nonspecific uptake, and undesired immune responses of cationic lipids. 46 LP experiments were performed according to the standard protocol, as previously described. 47 In order to compare LP with NPEG-PLL, cells were exposed to concentrations of siSurv corresponding to the amount delivered with NPEG-PLLs (i.e., 31 nM). As expected, western immunoblotting analysis showed a complete abrogation of survivin expression levels in PC-3 cells exposed to 31 nM LP-siSurv compared to cells exposed to only LP or LP-siScr ( Figure 7 ). Data in Figure 7 suggest a negligible down-modulation of survivin expression levels in cells exposed for 72 h to siSurv-loaded NPEG-PLLs when compared with siScr-loaded particles or pristine NPEG-PLLs (Figure 7a ). Chloroquine was also used to enhance cell transfection efficiency of NPEG-PLL by facilitating escape from acidic vesicles within a few hours. 48 Western immunoblotting analyses (Supporting Information, Figure S8 remarkable interference with the proliferation/viability of PC-3 cells (Figure 8 ). This evidence is in agreement with previous findings indicating that survivin down-regulation per se is not always able to induce tumor cell death, rather it contributes to enhancing the antitumor activity of radiation and/or chemotherapeutic agents. 50, 51 Based on these observations, the activity of a subtoxic concentration (30 nM, see control in Figure 8 ) of paclitaxel, an anticancer agent acting as mitotic inhibitor, was assessed. Specifically, the exposure of PC-3 to paclitaxel alone or in association with empty or siScr-loaded particles, did not significantly affect the viability of prostate cancer cells, whereas a significant (P<0.05) impairment of cell survival was observed in cells concomitantly exposed to the drug and siSurv-loaded particles ( Figure 8 ). levels (a survival factor). Such enhanced cytotoxic activity of paclitaxel in the presence of abrogated survivin expression levels obtained by using NPEG-PLLs is expected to result in reduced drug-dependent side effects, important when considering the dramatic side effects associated with the use of paclitaxel in the chemotherapeutic regimens.
Conclusions
NPEG-PLLs were engineered as redox-responsive and highly loaded depots, which allowed the sustained release of siRNA, leading to effective silencing of the target gene in prostate cancer cells. Our data show that the NPEG-PLLs are readily internalized by prostate cancer cells and exhibit no cytotoxicity or perturbations of the intracellular milieu (i.e., off-target effects) in cells exposed to high doses of empty redox-active NPEG-PLLs. The internalized particles were processed from endosomes to acidified compartments (pH 6) and degraded within 120 h in the cytosol. Our data showed a remarkable reduction in survivin amounts only upon a 120 h incubation of prostate cancer cells with siSurv-loaded NPEG-PLLs. However, only a low dose of surv-siRNA (30nM) is necessary to significantly silence the target gene. Finally, an enhanced and synergistic antitumor activity of a subtoxic dose of paclitaxel was observed when combined with the siSurv-NPEG-PLL-dependent down-regulation of the pro-survival factor survivin.
Translation of this promising nanoporous siRNA carrier from in vitro to in vivo models is envisaged. Further efforts are being made for testing nanometer sized NPEG-PLL porous particles in tumor-bearing mice models. To prolong circulation time and exploit the enhanced permeability and retention effect, nanometer sized porous silica template will be used to construct NPEG-PLLs.
This work paves the way for a further exploration of the co-delivery of chemotherapeutic drugs and siRNA within the single vector NPEG-PLL as a rational strategy for combined cancer therapy.
Supporting Information. Figure S1 (chemical structure of the NPEG-PLL), Figure S2 (potentiometric titration of NPEG-PLL), Figure S3 (degradation of NPEG-PLL by GSH and protease), Figure S4 (melting curve of native and released siRNA), Figure S5 
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